Accsys Technologies PLC (LON:AXS – Get Free Report) insider Louis Eperjesi bought 21,000 shares of the company’s stock in a ...

Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and keeping the price target ...

Axsome's AXS-12 reduces narcolepsy symptoms, positioning the company for success. Find out why AXSM stock is a buy with ...

Shares of AXIS Capital Holdings Limited (NYSE:AXS – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday after TD Cowen raised their price target on the stock from $118.00 to ...

AXS, with the stock showing a significant year-to-date increase of 64.7%. AXIS Capital’s market performance outpaces the ...

Cervélo dropped a bright Paris Green limited edition of their recently overhauled 2024 P-Series time trial & triathlon bike.

AXS-12 is an investigational highly selective potent norepinephrine reuptake inhibitor and cortical dopamine modulator.

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in ...

AXS First Priority CLO Bond ETF (NYSEARCA:AAA) declares income dividend of $0.1298. Payable Nov 01; for shareholders of ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Axsome Therapeutics (AXSM) announced that AXS-12 achieved the primary endpoint in the ENCORE Phase 3 trial, demonstrating a statistically ...